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Circadian biomarkers in patients with bipolar
disorder: promising putative predictors of lithium
response
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Abstract
Bipolar disorder (BD) is a common, severe mental disorder with a high recurrence rate. Lithium (Li) is the
cornerstone of BD treatments to reduce recurrence, suicide, and mortality risks. However, only 30% of patients
treated with Li achieve complete remission, and few markers of the response to treatment have yet been identified
for application in routine practice. Circadian biomarkers may be relevant predictors of individual responses to Li
because (1) Li has been shown to affect circadian rhythms, (2) disrupted circadian rhythms are a core expression of
susceptibility to BD, and (3) circadian abnormalities during euthymia are associated with relapses.
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Correspondence
Bipolar disorder (BD) is a common, severe mental dis-
order with an onset before the age of 21 years in half the
individuals affected (Geoffroy et al. 2013c; Phillips and
Kupfer 2013). BD impairs functioning and decreases
health-related quality of life. BD is the fourth most
important contributor to the global disease burden
among mental, neurological, and substance use disorders
(Scientific Advisory Board and the Executive Committee
of the Grand Challenges on Global Mental Health et al.
2011). The severity and poor prognosis of BD reflect the
high rate of recurrence, with a mean recurrence rate of
60% within 2 years of an index episode, despite medica-
tions (Geddes and Miklowitz 2013).
Lithium (Li) is the first-line treatment of BD and the
cornerstone of treatment for preventing relapses and re-
currences of any episodes of either polarity (Grunze
et al. 2009; Yatham et al. 2009; Goodwin 2009; Grunze
et al. 2010). Furthermore, it is the only treatment shown
to decrease suicide risk effectively (Yerevanian and Choi
2013). Li has also been shown to decrease the risk of
non-suicide mortality in patients with BD (Müller-
Oerlinghausen et al. 1992). However, naturalistic studies
have shown that about 40% of the BD patients treated
with Li show no improvement (non-responders, NRs),
about 30% are partial responders (PRs), and only 30% are
excellent responders (ERs), presenting complete remission
for two full years (Solomon et al. 1995; Maj et al. 1995;
Baldessarini and Tondo 2000; Garnham et al. 2007). In
addition, prophylactic efficacy can be evaluated only after
at least 2 years of treatment.
Few reliable and reproducible predictors of individual
responses to Li have been proposed: history of prophy-
lactic response to Li in first-degree relatives, course of
the episode, and complete remission between episodes
(Kleindienst et al. 2005). Other clinical markers have
been put forward, but their replication has been inconsist-
ent: manic-depressive sequence, age at onset, predominant
polarity, polarity of the first episode, BD subtype, atypical
features (mainly psychotic symptoms, interepisodic residual
symptomatology, and rapid cycling), comorbidities, and
temperaments (Garnham et al. 2007; Grof 2010; Schulze
et al. 2010; Pfennig et al. 2010; Rybakowski et al. 2013).
Thus, therapeutic response is variable, and it remains
difficult for clinicians to identify the patients most likely
to respond before lengthy Li trials. These data highlight
the need to identify biomarkers predictive of individual
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responses to Li, to improve care plans and the prognosis
of patients with BD. However, no such predictors have
yet been identified for application in routine practice
(Geoffroy et al. 2014).
Circadian biomarkers are potential markers for pre-
dicting the response to Li because Li is thought to help
stabilize circadian rhythms in BD and to prevent circa-
dian rhythm desynchronization (Klemfuss 1992). Indeed,
Li slightly lengthens the circadian period of behavioral
rhythms and delays the phase of behavioral and physio-
logical circadian rhythms (such as sleep-wakefulness
and body temperature rhythms) in many species, from
healthy and affected humans to rats (Johnsson et al.
1983; Pflug and Engelmann 1987; Klemfuss and Kripke
1995). The hypothesis of a circadian mode of action for
Li is of particular interest because patients with BD
present circadian abnormalities in all phases of the dis-
order (McClung 2007; Harvey 2008; Etain et al. 2011;
McClung 2013). Indeed, such abnormalities occur dur-
ing acute phases of depression (insomnia, early awaken-
ing, hypersomnia) and mania (decrease in the need for
sleep). In addition, circadian rhythm and sleep distur-
bances often precede recurrences and may serve as
predictors of a new mood episode. Some patients suffer
from seasonal recurrences of depression or mania: 25%
of BD patients for depression and 15% for mania (Geoffroy
et al. 2013a). These circadian abnormalities are also ob-
served during stable phases of normal mood (euthymia)
and are thus considered to be a ‘trait’ of BD. During euthy-
mia, BD patients are more likely than healthy controls to
present an evening chronotype, hypersensitivity to disrup-
tive rhythms (jet lag, post-partum, shift work, night vigils,
etc.), sleep/wake pattern abnormalities (sleep stability, sleep
latency and duration, waking after sleep onset, sleep quality,
diurnal activity, and daytime dysfunction), biochemical ab-
normalities, including melatonin secretion (sleep hormone)
and melatoninergic hypersensitivity to light (Hallam et al.
2006; McClung 2007, 2013).
Several independent genetic association studies have
implicated circadian or melatonin pathway genes, such
as CLOCK, GSK3β, NPAS2, ARNTL1, PER3, NR1D1,
and ASMT (Milhiet et al. 2011), in susceptibility to BD.
Polymorphisms associated with BD may be responsible
for circadian rhythm disturbances, as recently observed for
a common variant of ASMT associated with BD (Etain et al.
2012; Geoffroy et al. 2013b). Circadian rhythm instability,
through its contribution to the underlying neurobiology
and genetics of BD, appears to be a major candidate endo-
phenotype for studies aiming to identify the factors associ-
ated with treatment response in BD (Hasler et al. 2006).
Li acts at the molecular level, by modulating the dy-
namics of clock gene expression and protein rhythms in
the peripheral tissues and suprachiasmatic nuclei (the
central pacemaker of circadian rhythms) (Etain et al.
2011). For example, Li is known to affect the expression
of two key circadian genes, inhibiting GSK3β expression
and activating Clock transcription. It has also been
shown to rescue the manic-like behavior of mice trans-
genic for GSK3β and Clock (Prickaerts et al. 2006; Jope
and Roh 2006; Roybal et al. 2007). It is also suggested that
the neurobiological mechanisms by which Li influences cir-
cadian rhythms may involve Rev-Erbα, the protein product
of the NR1D1 gene, which is a phosphorylation target of
GSK3. Li inhibits GSK3 that in turn cannot phosphorylate
the Rev-Erbα protein which degrades (Can et al. 2014). Fur-
thermore, Li has demonstrated to improve diurnal activity
rhythm and periodic activity alterations in transgenic mice
with neuron-specific expression of mutant Polg (D181A) -
an animal model with generated chronobiological abnor-
malities (Kato et al. 2007).
Sleep and circadian rhythms are not only relevant can-
didates for the prediction of Li response. Many clinical
guidelines and documents have been developed governing
their exploration in routine clinical practice (Morgenthaler
et al. 2007a, b; Schutte-Rodin et al. 2008; Adult Obstructive
Sleep Apnea Task Force of the American Academy of
Sleep Medicine et al. 2009). Sleep logs or diaries, sleep or
morningness-eveningness questionnaires, and actigraphy
(a watch-like tool containing an accelerometer) are poten-
tially relevant and easy to implement in routine practice.
Actigraphy also appears to be useful for evaluating the
therapeutic response as an outcome measure (Morgenthaler
et al. 2007a).
In conclusion, disrupted circadian rhythms are a core
expression of susceptibility to BD, persistent circadian
abnormalities during euthymia are associated with re-
lapses, and Li is known to act on circadian rhythms.
Thus, circadian biomarkers are promising candidate bio-
markers for the study of individual response to Li but
cannot be used yet in clinical practice to predict this re-
sponse. Future researches that specifically address this
issue and prospective studies assessing the predictive
value of circadian biomarkers are therefore highly ex-
pected. Possible circadian studies of the molecular signa-
ture of the response to Li may also help to better
understand Li's action and to pave the way for more per-
sonalized medicine.
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